Summary of antiviral use
| . | D+/R+ . | D−/R+ . |
|---|---|---|
| No. of HCT recipients | 128 | 50 |
| Antiviral therapy (n) | 44% (56) | 56% (28) |
| Mean duration of therapy, d | 41 | 61 |
| Mean days per subject | 18 | 34 |
| > 6 weeks on antivirals (n) | 14% (18) | 28% (14) |
| > 7 weeks on antivirals (n) | 8% (10) | 20% (10) |
| Recurrent treatment (n) | 0.7% (1) | 16% (8) |
| . | D+/R+ . | D−/R+ . |
|---|---|---|
| No. of HCT recipients | 128 | 50 |
| Antiviral therapy (n) | 44% (56) | 56% (28) |
| Mean duration of therapy, d | 41 | 61 |
| Mean days per subject | 18 | 34 |
| > 6 weeks on antivirals (n) | 14% (18) | 28% (14) |
| > 7 weeks on antivirals (n) | 8% (10) | 20% (10) |
| Recurrent treatment (n) | 0.7% (1) | 16% (8) |
Antiviral therapy administration is summarized. The numbers (n) initiating antiviral therapy (GCV or FOS), duration of therapy, and recurrent treatment (after a 14-day hiatus) are presented.